Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Febie Irsandy Syahruddin,1 Prihantono,2 Mirna Muis3 1Department of Radiology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia; 2Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; 3Department of Radiology, Faculty of Medicine, Hasanuddin Uni...

Full description

Bibliographic Details
Main Authors:	Syahruddin FI, Prihantono, Muis M
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-04-01
Series:	Breast Cancer: Targets and Therapy
Subjects:	serum her2 breast cancer therapeutic efficacy prognosis
Online Access:	https://www.dovepress.com/serum-her2-level-predicts-therapeutic-efficacy-and-prognosis-in-adva-2-peer-reviewed-fulltext-article-BCTT

Similar Items

Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients
by: Wang S, et al.
Published: (2024-04-01)

Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer
by: Zhang P, et al.
Published: (2020-06-01)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
by: Elisa Agostinetto, et al.
Published: (2021-06-01)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
by: Xin Yang, et al.
Published: (2023-09-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
by: Hangcheng Xu, et al.
Published: (2022-06-01)

Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
by: Amir Shamshirian, et al.
Published: (2020-10-01)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
by: Atul Batra, et al.
Published: (2021-02-01)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
by: Guang-Yi Sun, et al.
Published: (2021-01-01)

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy
by: Feng QZ, et al.
Published: (2021-10-01)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
by: Hengqiang Zhao, et al.
Published: (2021-05-01)

Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients
by: Shayalini Wignarajah, et al.
Published: (2023-03-01)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer
by: Tomonori Tanei, et al.
Published: (2024-03-01)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
by: Lan Shu, et al.
Published: (2022-08-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis
by: Yun Wu, et al.
Published: (2022-09-01)

Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society
by: Hye Sung Won, et al.
Published: (2022-03-01)

Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer
by: Tong Wei, et al.
Published: (2024-03-01)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
by: Xiaohui Zhang, et al.
Published: (2021-08-01)

Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2‐low and HER2‐zero breast cancer among Chinese females
by: Lu Zheng, et al.
Published: (2023-07-01)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
by: Tomomi Sanomachi, et al.
Published: (2023-03-01)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
by: Chang-Gen Liu, et al.
Published: (2023-03-01)

HER2 Low Expression in Primary Male Breast Cancer
by: Nobbe K, et al.
Published: (2024-03-01)

Recurrent and Metastatic Characteristics and Prognosis of Advanced HER2-positive Breast Cancer Patients with Different HR Status
by: REN Yulin, et al.
Published: (2019-01-01)

Serum HER2 Level in Epithelial Ovarian Cancer
by: Ahmad Monabati, et al.
Published: (2010-04-01)

Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial
by: LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua
Published: (2024-02-01)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
by: Qian Wu, et al.
Published: (2023-10-01)

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
by: Mengting Wang, et al.
Published: (2022-09-01)

Reduced Expression of KRT17 Predicts Poor Prognosis in HER2<sup>high</sup> Breast Cancer
by: Shasha Tang, et al.
Published: (2022-08-01)

Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer
by: Hiba Hadi Rashid, et al.
Published: (2019-06-01)

Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer
by: Hiba Hadi Rashid, et al.
Published: (2019-06-01)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
by: A. Viansone, et al.
Published: (2022-10-01)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
by: Hong J, et al.
Published: (2019-04-01)

Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses
by: Suyu Gu, et al.
Published: (2024-04-01)

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
by: Wei Wang, et al.
Published: (2024-01-01)

Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression
by: Hui Zheng, et al.
Published: (2019-02-01)

The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
by: Yingying Zhao, et al.
Published: (2024-03-01)

New insights into HER2-low breast cancer brain metastasis: A retrospective analysis
by: Hangcheng Xu, et al.
Published: (2024-02-01)

Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis
by: Tong Wei, et al.
Published: (2023-02-01)